Zydelig is a kinase inhibitor indicated for the treatment of patients with Relapsed Small Lymphocytic Lymphoma (SLL) in patients who have received at least two prior systemic therapies

INN:

Subtype:

Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL)

License:

FDA

Class:

PI3K inhibitors

R/R

PI: http://www.gilead.com/~/media/files/pdfs/medicines/oncology/zydelig/zydelig_pi.pdf?la=en 

1. Approved Labelling

Zydelig is a kinase inhibitor indicated for the treatment of patients with relapsed Small Lymphocytic Lymphoma (SLL) in patients who have received at least two prior systemic therapies.

2. Treatment Regimen

The recommended maximum starting dose of Zydelig is 150 mg administered orally twice daily. Zydelig can be taken with or without food. Tablets should be swallowed whole. Continue treatment until disease progression or unacceptable toxicity. The optimal and safe dosing regimen for patients who receive treatment longer than several months is unknown.

3. AE/Warnings

Please see section 5 of the PI.

All content on this site is intended for healthcare professionals only. If you are a patient or carer, please visit the Lymphoma Coalition.